Description
Gluconolactone Peel 25%
Very superficial epidermal renewal, intensive hydration and strengthening of the skin barrier
Gluconolactone Peel 25% TherapDerma is a professional chemical peel formulated with 25% Gluconolactone, belonging to the Polyhydroxy Acid (PHA) family. It has been developed to promote very superficial, progressive and carefully controlled epidermal renewal, respecting skin physiology and preserving the integrity of the skin barrier.
Gluconolactone combines a gentle exfoliating action with a high humectant and antioxidant capacity, promoting the gradual reorganisation of the stratum corneum while helping to maintain hydration, improve skin comfort and optimise the superficial quality of the skin.
Its use may contribute to promoting more hydrated, radiant and even-looking skin, improving the appearance of fine expression lines, and being incorporated into professional protocols for properly selected sensitive or reactive skin, dehydrated skin, or skin with superficial texture irregularities.
What makes Gluconolactone Peel 25% different?
Not all chemical peels present the same clinical profile.
The main difference between Gluconolactone and other hydroxy acids lies in its high molecular weight and its excellent skin tolerance, characteristics that promote very superficial, gradual and even exfoliation.
In addition to promoting renewal of the stratum corneum, this Polyhydroxy Acid provides humectant and antioxidant properties that help preserve skin hydration and the physiological balance of the skin throughout treatment.
These characteristics make Gluconolactone Peel 25% a particularly suitable option when the objective is to perform highly tolerable procedures aimed at progressively improving the superficial quality of the skin.
________________________________________
What is Gluconolactone?
Gluconolactone is a Polyhydroxy Acid (PHA) widely used in aesthetic medicine because it combines very superficial chemical exfoliation with a high capacity to maintain skin hydration.
Its larger molecular size compared with Alpha Hydroxy Acids promotes slower and more progressive penetration, contributing to controlled epidermal renewal with an excellent tolerance profile.
In addition to promoting the gradual removal of superficial corneocytes, it possesses antioxidant and humectant properties that help maintain skin comfort, preserve the skin barrier and promote healthier, more balanced-looking skin.
________________________________________
When should Gluconolactone Peel 25% be chosen?
Gluconolactone Peel 25% may be considered when clinical assessment identifies the need for very superficial epidermal renewal associated with high skin tolerance and the maintenance of skin hydration.
It may be incorporated into professional protocols for patients presenting with:
• properly selected sensitive or reactive skin;
• skin dehydration;
• impaired skin barrier function;
• irregular superficial skin texture;
• fine expression lines;
• early photoageing;
• loss of radiance;
• dry, normal or combination skin;
• hydration and skin quality improvement programmes;
• periodic skin maintenance.
The indication should always be established following an individualised clinical assessment.
Clinical Benefits
Clinical benefits supported by the properties of Gluconolactone
Gluconolactone Peel 25% TherapDerma has been developed to provide very superficial chemical exfoliation combined with a high humectant and antioxidant capacity. Its physicochemical profile promotes gradual epidermal renewal while helping to maintain the physiological balance of the skin, making it a particularly suitable option for protocols intended for skin requiring a high level of cutaneous tolerance.
Clinical benefits should always be interpreted within a properly indicated professional protocol adapted to the individual characteristics of each patient.
________________________________________
💧 Intensive Hydration
What are the clinical benefits?
Gluconolactone has a remarkable ability to attract and retain water within the stratum corneum, helping to maintain balanced skin hydration throughout epidermal renewal protocols.
Clinical benefits
✔ Promotes prolonged superficial hydration.
✔ Helps maintain skin elasticity and flexibility.
✔ Contributes to skin comfort throughout treatment.
✔ Promotes healthier-looking skin.
________________________________________
✨ Very Superficial and Progressive Exfoliation
What are the clinical benefits?
Its exfoliating mechanism acts gradually on the most superficial layers of the epidermis, promoting even renewal without compromising the physiological balance of the skin.
Clinical benefits
✔ Promotes gradual epidermal renewal.
✔ Helps smooth the skin surface.
✔ Contributes to a more even skin texture.
✔ Offers a high tolerance profile.
________________________________________
🛡️ Maintenance of Skin Barrier Function
What are the clinical benefits?
Unlike other exfoliating agents, Gluconolactone makes it possible to carry out skin renewal protocols while helping to preserve the functional integrity of the epidermal barrier.
Clinical benefits
✔ Promotes the physiological balance of the skin.
✔ Helps preserve skin comfort.
✔ Contributes to maintaining epidermal hydration.
✔ Is particularly suitable for properly selected sensitive or reactive skin.
________________________________________
🌿 Antioxidant Protection
What are the clinical benefits?
Gluconolactone exhibits antioxidant activity, helping to protect the skin against oxidative stress associated with environmental factors and skin ageing.
Clinical benefits
✔ Contributes to protection against oxidative damage.
✔ Helps preserve skin quality.
✔ Promotes a healthier appearance.
✔ Complements professional skincare programmes.
________________________________________
🌟 Improved Radiance
What are the clinical benefits?
The combination of progressive exfoliation and hydration promotes a more even skin surface and a more uniform reflection of light.
Clinical benefits
✔ Promotes more radiant-looking skin.
✔ Contributes to a fresher appearance.
✔ Helps improve the skin’s visual vitality.
✔ Promotes a healthy appearance.
________________________________________
🎯 Refinement of Superficial Skin Texture
What are the clinical benefits?
The gradual reorganisation of the stratum corneum contributes to a smoother, more even skin surface.
Clinical benefits
✔ Promotes a more even skin texture.
✔ Helps smooth the skin microrelief.
✔ Contributes to reducing the sensation of roughness.
✔ Promotes improved superficial skin quality.
________________________________________
🌸 Visible Improvement in Skin Tone
What are the clinical benefits?
The even renewal of the most superficial layers of the epidermis may promote a more uniform appearance of skin tone.
Clinical benefits
✔ Promotes greater visible uniformity.
✔ Helps improve minor superficial irregularities.
✔ Contributes to more balanced-looking skin.
✔ Enhances the skin’s natural radiance.
________________________________________
📈 Cumulative Benefits
The benefits of Gluconolactone Peel 25% develop progressively as the professional protocol advances. Clinical outcomes will depend on the individual biological response, appropriate therapeutic planning and professional follow-up.
________________________________________
CLINICAL SUMMARY
Main benefits of Gluconolactone Peel 25%
✔ Intensive hydration.
✔ Very superficial and progressive exfoliation.
✔ Maintenance of skin barrier function.
✔ Antioxidant action.
✔ Improved radiance.
✔ Refinement of superficial skin texture.
✔ Greater visible uniformity of skin tone.
✔ Progressive benefits throughout the treatment.
Benefits
Dead skin cells are gently removed, causing no skin irritation. Gluconolactone is used for inflammatory skin diseases accompanied by hyperkeratosis: psoriasis, acne, dermatitis, anti-aging as a means of preventing and correcting age changes of the skin, especially sensitive ones. Due to the absence of irritating action, it does not require neutralization, it can be carried out often enough to achieve a noticeable effect.
Improves skin hydration, softens expression lines and wrinkles, increases skin elasticity, evens out skin tone due to keratolytic action, removes roughness and tightens pores. Gluconolactone does not cause irritation or sensitization of the skin and mucous membranes.
Why Choose Gluconolactone Peel 25%?
The clinical value lies in selecting the right peel for each patient
The choice of a professional chemical peel should always be based on the clinical diagnosis, the functional condition of the skin and the therapeutic objectives established for each patient.
Gluconolactone Peel 25% has been developed to be incorporated into protocols requiring very superficial exfoliation with a high tolerance profile, allowing progressive epidermal renewal to be combined with skin hydration and preservation of skin barrier function.
Its clinical profile makes it a particularly valuable option when the professional aims to improve overall skin quality through procedures that respect skin physiology and can be easily integrated into personalised Skin Quality programmes.
________________________________________
WHAT DOES IT OFFER COMPARED WITH OTHER PEELS?
The main distinguishing feature of Gluconolactone does not lie solely in its exfoliating capacity.
Its clinical value is based on combining several properties within a single procedure:
✔ very superficial and progressive exfoliation;
✔ high humectant capacity;
✔ support for the maintenance of skin barrier function;
✔ antioxidant action;
✔ excellent tolerance profile;
✔ high compatibility with protocols for properly selected sensitive skin.
These characteristics make it possible to develop treatments in which the priority is not to increase the intensity of exfoliation, but rather to preserve skin balance while progressively optimising Skin Quality.
________________________________________
WHEN CAN IT BE THE BEST CHOICE?
Gluconolactone Peel 25% may be particularly suitable when the therapeutic objective is to promote gentle epidermal renewal without compromising skin comfort or barrier function.
It may be appropriate in the presence of:
✔ properly selected sensitive or reactive skin;
✔ superficial dehydration;
✔ reduced skin comfort;
✔ functional impairment of the epidermal barrier;
✔ irregular superficial skin texture;
✔ loss of radiance;
✔ fine expression lines;
✔ early photoageing;
✔ the need for Skin Quality programmes.
The indication should always be established following an individualised clinical assessment.
________________________________________
WHAT IS ITS ROLE WITHIN THE THERAPEUTIC STRATEGY?
Gluconolactone Peel 25% is not intended to replace more intensive peels.
Its role is to occupy a specific clinical position within therapeutic planning, particularly when the professional wishes to prioritise:
✔ skin tolerance;
✔ hydration;
✔ maintenance of skin barrier function;
✔ progressive improvement in skin quality;
✔ maintenance protocols;
✔ Skin Quality strategies.
The choice of peel should always depend on the biological needs of the skin and not solely on the acid concentration.
________________________________________
THERAPDERMA CLINICAL LADDER™
Every peel has a different indication
The TherapDerma Clinical Ladder™ facilitates the selection of the most appropriate peel according to the clinical diagnosis and treatment objectives.
Gluconolactone Peel 25% occupies the level intended for protocols where the priority is:
✔ high skin tolerance;
✔ very superficial epidermal renewal;
✔ hydration;
✔ maintenance of skin barrier function;
✔ progressive improvement of Skin Quality.
The progression of treatment will always depend on the observed clinical response and the reassessment carried out by the professional.
________________________________________
WHY IS IT PART OF THE THERAPDERMA CLINICAL ECOSYSTEM™?
Modern aesthetic medicine is based on progressive and personalised therapeutic strategies.
For this reason, Gluconolactone Peel 25% may be incorporated as one phase within broader clinical programmes where appropriately indicated, subsequently integrating with other procedures following the skin’s physiological recovery.
This methodology makes it possible to build structured, individualised treatments adapted to the clinical progression of each patient.
________________________________________
CLINICAL SUMMARY
Gluconolactone Peel 25% stands out for:
✔ Very superficial epidermal renewal.
✔ High tolerance profile.
✔ Intensive hydration.
✔ Maintenance of skin barrier function.
✔ Antioxidant action.
✔ Progressive improvement of Skin Quality.
✔ An excellent option for programmes intended for properly selected sensitive skin.
✔ Integration within personalised therapeutic strategies.
Areas of Application
Anatomical adaptation within personalised protocols
Gluconolactone Peel 25% may be incorporated into different professional protocols when the clinical diagnosis confirms that there is an appropriate indication to promote very superficial epidermal renewal combined with intensive hydration and the progressive improvement of Skin Quality.
The selection of the anatomical area should always be based on clinical assessment, taking into account the functional characteristics of the skin, the integrity of the skin barrier function, the degree of sensitivity and the established therapeutic objectives.
Each region presents different biological behaviour. Therefore, the application technique, contact time and treatment planning should be individually adapted.
________________________________________
FACE
Primary area of application
The face is the most common indication for Gluconolactone Peel 25%, particularly within protocols aimed at improving hydration, promoting very superficial epidermal renewal and progressively optimising overall skin quality.
It may be considered when the clinical objective is to improve:
✔ skin hydration;
✔ superficial skin texture;
✔ radiance;
✔ visible uniformity of skin tone;
✔ fine expression lines;
✔ Skin Quality.
Application should be adapted to the different facial regions according to their sensitivity and clinical response.
________________________________________
NECK
Aesthetic continuity and preservation of skin barrier function
The skin of the neck has a lower sebaceous density and generally shows a greater tendency towards dehydration and sensitivity.
Where clinically indicated, Gluconolactone Peel 25% may be incorporated into protocols intended to:
✔ improve hydration;
✔ promote a more even skin texture;
✔ enhance radiance;
✔ maintain aesthetic continuity with the face.
The procedure should be performed with particular care due to the physiological characteristics of this region.
________________________________________
DÉCOLLETAGE
Progressive renewal of a photo-exposed area
The décolletage may benefit from protocols aimed at progressively improving the superficial quality of the skin where there is a professional indication.
Objectives may include:
✔ hydration;
✔ improved skin texture;
✔ enhanced radiance;
✔ visible uniformity of skin tone;
✔ optimisation of Skin Quality.
Planning should be individualised according to sensitivity and the observed response.
________________________________________
BACK OF THE HANDS
Progressive improvement of superficial skin quality
The backs of the hands are continuously exposed to environmental factors and may show visible signs of skin ageing.
Where indicated, Gluconolactone Peel 25% may be incorporated into protocols intended to:
✔ improve hydration;
✔ promote a more even skin texture;
✔ enhance radiance;
✔ optimise the superficial quality of the skin.
Application should always respect the individual’s recovery capacity.
________________________________________
BACK
Selected body application
In properly selected patients, Gluconolactone Peel 25% may be incorporated into body protocols aimed at promoting very superficial epidermal renewal.
It may contribute to the progressive improvement of:
✔ superficial hydration;
✔ skin texture;
✔ visible uniformity;
✔ radiance;
✔ Skin Quality.
The treatment area and frequency should be adapted according to the clinical progression.
________________________________________
CHEST
Localised protocols
When clinical assessment confirms adequate skin integrity, Gluconolactone Peel 25% may be used on localised areas of the chest to promote a progressive improvement in the superficial quality of the skin.
The indication should be carefully individualised, always avoiding areas with inflammatory processes, active lesions or impaired skin integrity.
________________________________________
CLINICAL GUIDANCE BY TREATMENT AREA
Area Main objective
Face Hydration, skin texture, radiance and Skin Quality.
Neck Hydration and aesthetic continuity.
Décolletage Hydration, radiance and visible uniformity.
Back of the hands Hydration and improvement of superficial skin quality.
Back Very superficial epidermal renewal and improved skin texture.
Chest Localised optimisation of skin quality.
________________________________________
CLINICAL CONSIDERATIONS
The indication for each treatment area should be established following an individualised clinical assessment.
Before each procedure, it is recommended to assess:
✔ integrity of skin barrier function;
✔ skin sensitivity;
✔ hydration level;
✔ relevant medical history;
✔ previous treatments;
✔ the skin’s recovery capacity.
The application technique should always be adapted to the anatomical and functional characteristics of each region.
________________________________________
QUICK SUMMARY
Most common areas of application
✔ Face.
✔ Neck.
✔ Décolletage.
✔ Back of the hands.
✔ Back.
✔ Chest.
Clinical objectives
✔ Very superficial epidermal renewal.
✔ Intensive hydration.
✔ Preservation of skin barrier function.
✔ Improved skin texture.
✔ Enhanced radiance.
✔ Visible uniformity of skin tone.
✔ Progressive optimisation of Skin Quality.
________________________________________
THERAPDERMA CONCLUSION
Gluconolactone Peel 25% may be incorporated into different anatomical areas where there is an appropriate clinical indication and therapeutic planning respects the biological characteristics of each region.
Its application should be individualised according to the diagnosis, the observed clinical response and the established therapeutic objectives, always maintaining an approach focused on safety, preservation of skin barrier function and the progressive improvement of Skin Quality.
________________________________________
Changes made to avoid repetition
• I removed repeated explanations regarding skin barrier function, hydration and skin physiology, which have already been covered in Tabs 1 and 2.
• I removed the repetition of identical lists of benefits for each anatomical area.
• I removed the “Multi-Area Protocols” section, as this concept is developed much more thoroughly in the Clinical Protocols and TherapDerma™ Combinations tabs.
• I simplified the table so that it functions as a quick reference guide without repeating clinical information that will appear in the Indications and Protocols tabs.
• I kept this tab focused exclusively on where the peel may be applied and the objectives pursued in each anatomical area, which is the natural purpose of an Areas of Application tab.
How Does It Work?
Understanding the progression of treatment allows a better interpretation of the skin’s response
The application of Gluconolactone Peel 25% TherapDerma is carried out over a limited period of time, but skin evolution continues after the session has ended.
Its action promotes very superficial and progressive epidermal renewal. As accumulated corneocytes are gradually eliminated, the skin surface may develop a smoother, more even, hydrated and radiant appearance.
The response should not be assessed solely by the presence of visible peeling. With Gluconolactone peels, the progression may be subtle and gradual, particularly in patients with sensitive skin or low tolerance to more intensive exfoliation.
________________________________________
STEP 1
Controlled application to the skin surface
The product is applied to the previously prepared treatment area using a uniform technique and a contact time adapted to the characteristics of the skin.
During this phase, the professional monitors:
✔ the level of comfort reported by the patient;
✔ the appearance of erythema;
✔ differences in response between treatment areas;
✔ overall tolerance of the procedure;
✔ any sign that justifies ending the application earlier than planned.
The observed clinical response should always take precedence over an automatically predetermined contact time.
________________________________________
STEP 2
Gradual removal of superficial skin cells
Following application, a very superficial exfoliation begins, facilitating the progressive removal of accumulated corneocytes.
This renewal may occur without marked visible peeling. During the following days, the skin may show only subtle changes, such as increased smoothness or a more even texture.
The intensity of the response may vary according to:
✔ the treatment area;
✔ the thickness of the skin surface;
✔ the amount applied;
✔ the contact time;
✔ individual sensitivity;
✔ the previous condition of the skin;
✔ treatments previously performed.
________________________________________
STEP 3
Progressive reorganisation of the skin surface
As the removal of superficial skin cells progresses, the stratum corneum may develop a more even structure.
During this phase, the following may progressively be observed:
✔ reduced sensation of roughness;
✔ a smoother skin surface;
✔ a more even appearance;
✔ improved light reflection;
✔ greater skin comfort.
The progression may differ from one patient to another and should not be compared solely on the basis of the degree of visible peeling.
________________________________________
STEP 4
Improvement in skin appearance and comfort
The combination of superficial renewal and hydration promotes visually more balanced skin.
As recovery progresses, the following may become apparent:
✔ increased smoothness;
✔ progressive improvement in radiance;
✔ a more even skin texture;
✔ reduced sensation of tightness;
✔ a fresher appearance;
✔ visible softening of fine lines associated with dehydration.
These changes should be assessed within the objectives established before treatment begins.
________________________________________
STEP 5
Recovery after the procedure
During the following days, the skin should remain protected and supported with appropriate home care.
The usual progression may include:
✔ absence of visible peeling;
✔ minimal peeling;
✔ slight temporary sensitivity;
✔ a progressive sensation of smoothness;
✔ gradual recovery of skin comfort;
✔ visible improvement in radiance.
The patient should not manually remove any peeling skin or introduce exfoliating products until further professional advice has been provided.
________________________________________
STEP 6
Reassessment before continuing
A new session should not be scheduled automatically.
Before proceeding, the professional should assess:
✔ tolerance of the previous procedure;
✔ complete recovery of the skin;
✔ absence of persistent irritation;
✔ the evolution of skin texture;
✔ changes in hydration and comfort;
✔ the response in radiance;
✔ compliance with post-treatment care;
✔ the genuine need to maintain or modify the protocol.
The treatment frequency should be adapted to the observed clinical progression rather than to a fixed schedule.
________________________________________
WHY CAN VISIBLE PEELING BE MINIMAL?
Gluconolactone Peel 25% is intended to provide very superficial and gradual action.
For this reason, some patients may experience only very subtle visible renewal without significant peeling.
The absence of marked peeling does not indicate an absence of activity. The response should be assessed through the combined evolution of:
✔ smoothness;
✔ hydration;
✔ comfort;
✔ texture;
✔ radiance;
✔ visible skin uniformity.
________________________________________
A DIFFERENT RESPONSE IN EVERY PATIENT
Two patients treated with the same product may experience different clinical outcomes.
Some skins show rapid improvement in comfort and smoothness, while others require several sessions before changes in texture, radiance or uniformity become more evident.
This variability may be related to:
✔ the initial condition of the skin;
✔ individual sensitivity;
✔ the treatment area;
✔ previous treatments;
✔ the home care routine;
✔ environmental exposure;
✔ recovery capacity.
Observing the actual clinical progression allows subsequent sessions to be adapted more precisely.
________________________________________
TREATMENT SEQUENCE
Professional application
↓
Very superficial exfoliation
↓
Gradual removal of accumulated corneocytes
↓
Reorganisation of the skin surface
↓
Progressive improvement in smoothness and comfort
↓
Recovery of radiance
↓
Professional reassessment
↓
Continuation, adaptation or completion of the protocol
________________________________________
KEY POINTS FOR INTERPRETING THE PROGRESSION
✔ Visible peeling is not essential.
✔ Greater intensity does not necessarily mean a better result.
✔ The progression may continue during the days following treatment.
✔ The response should be assessed using several parameters rather than a single sign.
✔ Every new session requires reassessment.
✔ Complete skin recovery is the main criterion for continuing treatment.
________________________________________
THERAPDERMA CONCLUSION
Gluconolactone Peel 25% works through very superficial and progressive renewal, the progression of which may be subtle, cumulative and different for each patient.
Appropriate follow-up allows changes in smoothness, hydration, comfort, texture and radiance to be assessed without using the intensity of visible peeling as the primary indicator of efficacy.
Understanding this progression helps the professional establish realistic expectations, correctly interpret the response and make well-founded decisions on when to maintain, adapt or complete the treatment protocol.
Mechanism of Action
The science behind the biological response of Gluconolactone
The mechanism of action of Gluconolactone Peel 25% TherapDerma is based on the interaction between Gluconolactone, the formulation’s pH, the contact time and the functional characteristics of the stratum corneum.
As a Polyhydroxy Acid (PHA), Gluconolactone has a larger molecular structure than many Alpha Hydroxy Acids, resulting in slower diffusion across the skin surface and predominantly superficial activity.
Its action combines three main mechanisms:
✔ gradual modulation of corneocyte cohesion;
✔ interaction with the water present in the stratum corneum;
✔ antioxidant and chelating activity.
________________________________________
ACTION ON THE STRATUM CORNEUM
The stratum corneum is composed of corneocytes surrounded by an organised lipid matrix.
This structure performs essential functions:
✔ limiting transepidermal water loss;
✔ protecting against external agents;
✔ maintaining cohesion of the skin surface;
✔ regulating epidermal permeability.
Gluconolactone Peel 25% acts primarily at this level by gradually modifying the interactions responsible for adhesion between superficial corneocytes.
Its activity remains predominantly confined to the outer layers of the epidermis, which explains its very superficial exfoliating profile.
________________________________________
MODULATION OF CORNEODESMOSOMES
Corneocytes are held together by protein structures known as corneodesmosomes.
During physiological desquamation, these structures are progressively degraded, allowing the natural shedding of cells that have completed their differentiation cycle.
Gluconolactone promotes a gradual reduction in corneocyte cohesion, facilitating this process of superficial cell shedding.
The result is a more orderly removal of accumulated corneocytes and a progressive reorganisation of the epidermal surface.
This mechanism may occur without producing marked macroscopic peeling.
________________________________________
MOLECULAR SIZE AND PENETRATION RATE
Gluconolactone has an approximate molecular weight of 178.14 g/mol, which is higher than that of several hydroxy acids used in chemical peels.
This characteristic reduces the rate at which the active ingredient passes through the stratum corneum.
From a clinical perspective, slower penetration promotes:
✔ progressive distribution of the active ingredient;
✔ predominantly superficial activity;
✔ lower immediate concentration of the chemical stimulus in deeper layers;
✔ greater control during application.
Molecular size alone does not determine the final response, but it is one of the factors that differentiates the behaviour of PHAs from other hydroxy acids.
________________________________________
INTERACTION WITH WATER
The structure of Gluconolactone contains several hydroxyl groups capable of forming bonds with water molecules.
This characteristic provides humectant properties and promotes interaction with the water content of the stratum corneum.
From a physiological perspective, this behaviour may contribute to:
✔ increasing water availability on the epidermal surface;
✔ maintaining corneocyte flexibility;
✔ promoting a less rigid superficial matrix;
✔ reducing the sensation of dryness associated with the exfoliation process.
Its humectant activity is part of the active ingredient’s molecular behaviour and should not be confused with an occlusive effect.
________________________________________
RELATIONSHIP WITH THE ACID MANTLE
The acid mantle plays a role in regulating the homeostasis of the skin surface.
Its pH influences processes such as:
✔ enzymatic activity within the stratum corneum;
✔ organisation of epidermal lipids;
✔ cohesion between corneocytes;
✔ the functional integrity of the skin barrier.
The application of an acidic formulation temporarily modifies the chemical environment of the skin surface.
This variation may influence the enzymes involved in physiological desquamation and the reorganisation of the stratum corneum.
The magnitude of this response depends on the final pH of the formulation, the contact time and the previous condition of the skin.
________________________________________
ANTIOXIDANT AND CHELATING ACTIVITY
Gluconolactone is capable of interacting with certain metal ions involved in oxidative reactions.
Through this chelating action, it may partially reduce the availability of metals that participate in the formation of reactive oxygen species.
This mechanism helps complement the skin’s physiological antioxidant systems against factors such as:
✔ ultraviolet radiation;
✔ environmental pollution;
✔ oxidative processes associated with skin ageing;
✔ cumulative exposure to external agents.
The antioxidant activity of the active ingredient is complementary and does not replace photoprotection.
________________________________________
RELATIONSHIP BETWEEN CONCENTRATION, pH AND ACTIVITY
The 25% concentration indicates the nominal amount of Gluconolactone present in the formulation but does not, on its own, predict its clinical behaviour.
Final activity depends on the interaction between:
✔ total concentration;
✔ formulation pH;
✔ degree of ionisation;
✔ vehicle;
✔ formulation stability;
✔ amount applied;
✔ contact time;
✔ number of layers;
✔ hydration of the stratum corneum;
✔ integrity of the epidermal barrier.
Two formulations with the same concentration may produce different responses if any of these parameters vary.
________________________________________
GLUCONOLACTONE–GLUCONIC ACID EQUILIBRIUM
Gluconolactone is the lactone form of Gluconic Acid.
In the presence of water, gradual opening of the lactone ring may occur, establishing an equilibrium with Gluconic Acid.
This process influences the chemical availability of the system and its interaction with the cutaneous environment.
The behaviour of the formulation should therefore be interpreted as the result of a dynamic equilibrium rather than the isolated action of a single molecular species.
________________________________________
SCIENCE AT A GLANCE™
Parameter Gluconolactone Peel 25%
Active ingredient Gluconolactone
Chemical family Polyhydroxy Acids (PHA)
Molecular formula C₆H₁₀O₆
Molecular weight 178.14 g/mol
Primary site of action Stratum corneum
Exfoliating mechanism Gradual reduction of corneocyte cohesion
Structure involved Corneodesmosomes
Penetration rate Slow and progressive
Humectant property Interaction through multiple hydroxyl groups
Complementary action Antioxidant and chelating
Regulatory factors Concentration, pH, vehicle, contact time and skin condition
Type of action Very superficial
________________________________________
SIMPLIFIED BIOCHEMICAL SEQUENCE
Application of the formulation
↓
Interaction with the acid mantle and the stratum corneum
↓
Progressive modulation of corneocyte cohesion
↓
Facilitation of physiological desquamation
↓
Reorganisation of the epidermal surface
Simultaneously:
Interaction with water molecules
↓
Maintenance of superficial hydration
And:
Chelation of selected metal ions
↓
Support against oxidative processes
________________________________________
VARIABLES THAT MODIFY THE RESPONSE
The intensity of the response may vary according to:
✔ thickness of the stratum corneum;
✔ hydration level;
✔ amount of superficial sebum;
✔ integrity of the skin barrier;
✔ anatomical region;
✔ skin temperature;
✔ prior skin preparation;
✔ amount applied;
✔ exposure time;
✔ treatments previously performed.
These variables explain why the same formulation may behave differently between patients or between different areas of the same individual.
________________________________________
THERAPDERMA CONCLUSION
The mechanism of action of Gluconolactone Peel 25% is based on a predominantly superficial interaction with the stratum corneum.
Its larger molecular size results in gradual penetration, while its action on corneocyte cohesion facilitates the physiological desquamation of superficial skin cells.
This exfoliating mechanism is complemented by its ability to interact with water and by its antioxidant and chelating activity.
The final behaviour of the formulation depends on the relationship between concentration, pH, vehicle, contact time and the functional characteristics of the skin.
Scientific Foundations
The formulation determines clinical behaviour
In a professional chemical peel, the declared concentration of the active ingredient constitutes only part of the information required to interpret its behaviour.
The response of a formulation depends on the interaction between:
✔ concentration;
✔ pH;
✔ chemical equilibrium of the active ingredient;
✔ vehicle and excipients;
✔ physicochemical stability;
✔ uniformity of application;
✔ effective contact time;
✔ functional condition of the skin.
For this reason, two peels with the same nominal concentration may present different activity profiles.
In Gluconolactone Peel 25% TherapDerma, scientific interpretation should consider the formulation as a complete system and not as a simple 25% Gluconolactone solution.
________________________________________
CONCENTRATION
A quantitative parameter, not an isolated measure of intensity
Concentration expresses the nominal amount of Gluconolactone present in the formulation.
However, it does not determine on its own:
✔ the functional availability of the active ingredient;
✔ the rate of interaction with the skin surface;
✔ the intensity of the response;
✔ the degree of tolerance;
✔ the duration of the chemical effect.
A 25% concentration of a PHA cannot be directly compared with the same percentage of an AHA or a BHA.
Each hydroxy acid family presents structural, physicochemical and functional differences that determine its behaviour on the skin.
Therefore, the percentage should be interpreted together with the pH, the vehicle and the specific technical instructions for the formulation.
________________________________________
THE ROLE OF pH
The regulator of the chemical environment
pH indicates the degree of acidity of the formulation and constitutes one of the factors that most influence the chemical availability of the system.
Small variations may modify:
✔ the equilibrium between the chemical species present;
✔ the ionised and non-ionised fraction;
✔ the interaction of the active ingredient with the stratum corneum;
✔ the stability of the preparation;
✔ the behaviour observed during the procedure.
The available technical documentation places the pH of Gluconolactone Peel 25% above 3.5.
This information should be interpreted in combination with the concentration of the active ingredient and the other characteristics of the formulation.
pH should not be analysed as an isolated indicator of safety or efficacy.
________________________________________
THE MEANING OF pKa
Interpreting the Gluconolactone–Gluconic Acid equilibrium
pKa describes the equilibrium between the ionised and non-ionised forms of an acid according to the pH of the medium.
Gluconolactone is a lactone which, in the presence of water, may gradually convert into Gluconic Acid. For this reason, the pKa value used as a reference corresponds to the system associated with Gluconic Acid:
Reference pKa ≈ 3.6
The relationship between the pH of the formulation and this value helps provide a better understanding of the distribution of the available chemical species.
However, pKa does not independently predict the clinical response.
It should be interpreted together with:
✔ concentration;
✔ vehicle;
✔ stability;
✔ contact time;
✔ application conditions;
✔ condition of the skin surface.
________________________________________
GLUCONOLACTONE–GLUCONIC ACID EQUILIBRIUM
A dynamic chemical system
In an aqueous medium, Gluconolactone may undergo progressive opening of its molecular ring and establish an equilibrium with Gluconic Acid.
This process means that the formulation should not be interpreted as a chemically static substance.
The existing equilibrium may depend on:
✔ water content;
✔ pH;
✔ temperature;
✔ time;
✔ vehicle composition;
✔ storage conditions.
The stability of the system is essential to maintain uniform and reproducible behaviour throughout its shelf life.
________________________________________
PHYSICOCHEMICAL PROFILE OF GLUCONOLACTONE
Characteristics of the active ingredient
Gluconolactone belongs to the Polyhydroxy Acid family and chemically corresponds to the lactone form of Gluconic Acid.
It is a water-soluble, polyhydroxylated molecule with several functional groups capable of interacting with the aqueous environment of the formulation.
SCIENTIFIC MOLECULAR PROFILE™
Parameter Gluconolactone
Chemical name D-Glucono-1,5-lactone
Cosmetic designation Gluconolactone
Chemical family Polyhydroxy Acid (PHA)
Molecular formula C₆H₁₀O₆
Molecular weight 178.14 g/mol
Chemical nature Water-soluble polyhydroxylated lactone
Related system Gluconolactone–Gluconic Acid
Reference pKa ≈ 3.6, corresponding to Gluconic Acid
Chemical origin Derived from the oxidation of glucose
Solubility Soluble in water
Structural characteristic Presence of multiple hydroxyl groups
These properties describe the active ingredient but do not replace the assessment of the complete formulation.
________________________________________
THE VEHICLE
The functional architecture of the peel
The vehicle determines how the active ingredient is incorporated, distributed and maintained within the formulation.
It may influence:
✔ the solubility of Gluconolactone;
✔ product uniformity;
✔ viscosity;
✔ ease of spreading;
✔ retention on the treated surface;
✔ chemical stability;
✔ reproducibility between applications.
The same concentration of Gluconolactone may behave differently when the vehicle is modified.
Therefore, it is not scientifically correct to compare two peels solely on the basis of the declared percentage.
________________________________________
EXCIPIENTS AND STABILITY
Components that determine formulation quality
Excipients are not secondary elements without functional relevance.
Their selection may contribute to:
✔ maintaining the pH within the intended range;
✔ supporting the stability of the active ingredient;
✔ controlling viscosity;
✔ improving uniform distribution;
✔ protecting the formulation against physical or chemical changes;
✔ preserving its characteristics during storage.
Stability should be maintained under the conditions indicated by the manufacturer.
Visible changes in colour, odour, clarity or consistency may indicate product alteration and require assessment before use.
________________________________________
FUNCTIONAL AVAILABILITY OF THE ACTIVE INGREDIENT
Total concentration does not equal immediate activity
The total amount of Gluconolactone present does not necessarily represent the fraction that interacts immediately with the skin surface.
Functional availability is influenced by:
✔ the degree of dissolution;
✔ the equilibrium with Gluconic Acid;
✔ pH;
✔ vehicle composition;
✔ temperature;
✔ contact time;
✔ amount applied.
This difference between nominal concentration and functional availability explains why an interpretation based exclusively on percentage is insufficient when assessing a chemical peel.
________________________________________
UNIFORMITY AND REPRODUCIBILITY
Two essential requirements of a professional formulation
A professional formulation should promote uniform distribution of the active ingredient and maintain consistent characteristics between different applications.
Reproducibility depends on:
✔ product stability;
✔ correct storage;
✔ uniformity before application;
✔ use within the validity period;
✔ compliance with storage conditions;
✔ consistent professional technique;
✔ control of the amount applied.
The quality of a formulation is not limited to its initial composition, but also includes its ability to maintain stable behaviour throughout its use.
________________________________________
WHY CAN TWO FORMULATIONS BEHAVE DIFFERENTLY?
Although two products may state “25% Gluconolactone”, they may differ in:
✔ pH;
✔ purity and quality of the raw materials;
✔ water content;
✔ vehicle;
✔ excipients;
✔ viscosity;
✔ stability;
✔ packaging system;
✔ storage conditions;
✔ uniformity of distribution;
✔ application instructions.
These differences may alter the availability of the active ingredient and the overall behaviour of the product.
Professional comparison should consider the complete technical data sheet and not only the commercial name or concentration.
________________________________________
FACTORS THAT DETERMINE THE BEHAVIOUR OF THE FORMULATION
FORMULATION
✔ Nominal concentration.
✔ pH.
✔ Gluconolactone–Gluconic Acid equilibrium.
✔ Vehicle.
✔ Excipients.
✔ Stability.
✔ Viscosity.
↓
CONDITIONS OF USE
✔ Amount applied.
✔ Uniformity of distribution.
✔ Contact time.
✔ Environmental and skin temperature.
✔ Product storage conditions.
↓
SKIN SURFACE
✔ Water content.
✔ Presence of sebum or residues.
✔ Thickness of the stratum corneum.
✔ Epidermal integrity.
✔ Anatomical region.
↓
OBSERVED BEHAVIOUR
This integrated approach allows a more rigorous interpretation of the differences between apparently equivalent formulations.
________________________________________
SCIENTIFIC FORMULATION PROFILE™
Parameter Gluconolactone Peel 25%
Active ingredient Gluconolactone
Nominal concentration 25%
Chemical family Polyhydroxy Acid (PHA)
Molecular formula of the active ingredient C₆H₁₀O₆
Molecular weight of the active ingredient 178.14 g/mol
Related chemical system Gluconolactone–Gluconic Acid
Reference pKa ≈ 3.6
pH stated in the technical documentation Above 3.5
Nature of the active ingredient Water-soluble polyhydroxylated lactone
Professional presentation 1 vial of 5 mL
Intended use Professional use only
Scientific note: the available information makes it possible to describe the active ingredient, its concentration and the stated pH range. The complete composition of the vehicle and excipients should be consulted in the manufacturer’s official technical documentation.
________________________________________
PRINCIPLES FOR INTERPRETING THE FORMULATION
✔ Concentration alone does not equate to clinical intensity.
✔ pH modifies the chemical equilibrium of the system.
✔ The pKa used as a reference corresponds to Gluconic Acid.
✔ Gluconolactone may gradually convert into Gluconic Acid in the presence of water.
✔ The vehicle determines the distribution and availability of the active ingredient.
✔ Excipients influence stability and uniformity.
✔ Two products with the same concentration may behave differently.
✔ Complete technical documentation forms the basis for comparing formulations.
________________________________________
THERAPDERMA SCIENTIFIC INSIGHT™
Scientifically interpreting Gluconolactone Peel 25% means analysing the formulation as a dynamic chemical system.
The 25% concentration provides quantitative information, but its behaviour can only be understood when studied together with the pH, the Gluconolactone–Gluconic Acid equilibrium, the vehicle, the excipients and the stability of the preparation.
This approach distinguishes scientific knowledge from a simplified interpretation based exclusively on the percentage of the active ingredient.
________________________________________
THERAPDERMA CONCLUSION
The scientific foundations of Gluconolactone Peel 25% are based on the relationship between the molecular nature of Gluconolactone and the overall characteristics of the formulation.
The pH, chemical equilibrium with Gluconic Acid, vehicle, excipients and stability determine how the active ingredient is maintained and distributed before and during use.
For this reason, professional interpretation of the formulation should always be based on the complete set of technical parameters and not solely on the declared nominal concentration.
Indications
When should Gluconolactone Peel 25% be chosen?
The indication for Gluconolactone Peel 25% should be established when professional assessment identifies predominantly superficial alterations that may benefit from gradual exfoliation with a high tolerance profile.
It is particularly relevant in patients whose skin requires a controlled approach, avoiding more intensive exfoliating stimuli. The skin surface should be intact, stable and free from signs of active inflammation.
________________________________________
CLINICAL PATIENT PROFILE
It may be considered in patients presenting with one or more of the following characteristics:
✔ clinically stable sensitive skin;
✔ reactive skin without active erythema or irritation;
✔ epidermal dehydration;
✔ sensation of tightness;
✔ rough or irregular texture;
✔ loss of superficial smoothness and flexibility;
✔ fine lines accentuated by dehydration;
✔ reduced radiance;
✔ mild epidermal irregularities in skin tone;
✔ superficial comedones or visible pores in low-tolerance skin;
✔ early signs of photoageing;
✔ the need for particularly gradual exfoliation.
The presence of these characteristics does not constitute an automatic indication. They should be assessed together with skin integrity, the patient’s history and the purpose of treatment.
________________________________________
MAIN INDICATIONS
STABLE SENSITIVE OR REACTIVE SKIN
It may be considered when the skin presents reduced tolerance to certain cosmetics or procedures but retains an intact and clinically stable surface.
The indication may be aimed at:
✔ promoting controlled superficial renewal;
✔ improving uneven skin texture;
✔ reducing the sensation of roughness;
✔ progressively restoring comfort;
✔ offering an alternative to more intensive exfoliation.
It should not be applied to inflamed or irritated skin or where skin barrier function is clearly compromised.
________________________________________
EPIDERMAL DEHYDRATION
It may be incorporated when superficial water loss is manifested by:
✔ tightness;
✔ reduced flexibility;
✔ rough texture;
✔ a dull appearance;
✔ increased visible prominence of fine lines.
In these cases, the peel may form part of a professional strategy combining superficial renewal with adapted hydrating care.
________________________________________
ROUGH OR IRREGULAR TEXTURE
It is indicated where there is a superficial accumulation of corneocytes that alters the microrelief and produces skin that is less even to the touch or in appearance.
It may be considered to:
✔ progressively smooth the surface;
✔ improve the regularity of the microrelief;
✔ reduce a rough appearance;
✔ promote visibly more even-looking skin.
________________________________________
LOSS OF RADIANCE
It may be incorporated into protocols for dull skin where reduced light reflection is associated with dehydration or superficial corneocyte accumulation.
The indication is particularly appropriate when the objective is to restore a fresher appearance without initially using a more intensive peel.
________________________________________
FINE LINES ASSOCIATED WITH DEHYDRATION
Superficial lines may become more visible when hydration and flexibility within the stratum corneum decrease.
Gluconolactone Peel 25% may be considered to visibly improve these lines when their predominant component is superficial rather than structural.
It is not intended to correct deep wrinkles or advanced dermal alterations.
________________________________________
SUPERFICIAL SKIN TONE IRREGULARITIES
It may form part of protocols aimed at minor visible irregularities located within the most superficial epidermal layers.
Before establishing the indication, the following should be assessed:
✔ the origin of the alteration;
✔ its probable depth;
✔ its distribution;
✔ phototype;
✔ pigmentation history;
✔ sun exposure;
✔ the risk of post-inflammatory hyperpigmentation.
Deep or undiagnosed pigmentation irregularities require specific assessment.
________________________________________
COMEDONES AND VISIBLE PORES
In patients with low tolerance to more intensive exfoliation, it may be considered as supportive care within gentle protocols for:
✔ open or closed comedones;
✔ blackheads;
✔ visibly enlarged pores;
✔ mild seborrhoea;
✔ irregular follicular texture.
It does not replace the specific management of moderate or severe inflammatory acne.
________________________________________
EARLY PHOTOAGEING
It may be incorporated when the first signs of cumulative exposure are manifested by:
✔ dehydration;
✔ irregular skin texture;
✔ reduced radiance;
✔ fine lines;
✔ visibly uneven skin tone.
Its role is limited to superficial changes and should be accompanied by photoprotection and appropriate home care.
________________________________________
INDICATION WITHIN MAINTENANCE PROGRAMMES
Gluconolactone Peel 25% may also be considered after the initial objectives have been achieved, where the professional considers it appropriate to maintain periodically:
✔ the smoothness of the skin surface;
✔ radiance;
✔ comfort;
✔ regularity of texture;
✔ epidermal hydration.
Frequency should be determined through reassessment rather than an automatic schedule.
________________________________________
SELECTION CRITERIA
Before indicating the procedure, it should be confirmed:
✔ that the alteration is predominantly superficial;
✔ that the skin is intact and stable;
✔ that there is no active infection, inflammation or irritation;
✔ that skin barrier function allows the peel to be performed;
✔ that the objective is compatible with gradual activity;
✔ that the patient’s expectations are realistic;
✔ that post-treatment care can be followed;
✔ that the expected tolerance profile justifies the choice of a PHA.
________________________________________
QUICK INDICATION GUIDE
Clinical situation Assessment
Stable sensitive skin May be considered
Reactive skin without active inflammation May be considered with a conservative protocol
Superficial dehydration Relevant indication
Rough or irregular texture May be considered
Fine lines caused by dehydration May be considered
Reduced radiance May be considered
Mild epidermal skin tone irregularities Requires prior diagnosis
Superficial comedones in sensitive skin May be incorporated as supportive care
Early photoageing May form part of the programme
Inflammation, irritation or compromised barrier Postpone the procedure
Moderate or severe inflammatory acne Consider another strategy
Deep or undiagnosed pigmentation Carry out specific assessment
________________________________________
CLINICAL SUMMARY
Gluconolactone Peel 25% may be considered primarily in patients with:
✔ stable skin sensitivity;
✔ epidermal dehydration;
✔ tightness or loss of comfort;
✔ irregular superficial texture;
✔ reduced radiance;
✔ fine lines associated with dryness;
✔ mild epidermal skin tone irregularities;
✔ superficial comedones or visible pores;
✔ early signs of photoageing;
✔ the need for maintenance through gradual exfoliation.
The definitive indication will always depend on the skin presenting suitable conditions for the procedure and on the clinical objective being compatible with very superficial activity.
Contraindications
Situations in which the procedure should be avoided or postponed
The good tolerance associated with Gluconolactone does not eliminate the possibility of irritation or replace prior professional assessment.
Gluconolactone Peel 25% should not be applied when the skin presents conditions that increase the risk of a reaction, compromise its integrity or hinder appropriate recovery.
________________________________________
ABSOLUTE CONTRAINDICATIONS
PREGNANCY AND BREASTFEEDING
As a precautionary measure, the procedure is not recommended during pregnancy or breastfeeding.
________________________________________
HYPERSENSITIVITY TO THE FORMULATION
It is contraindicated in patients with a known history of allergy or hypersensitivity to Gluconolactone or any of the product’s components.
It should also be avoided where there has been a previous severe or unexplained reaction to similar chemical peels.
________________________________________
ACTIVE SKIN INFECTIONS
It should not be applied to areas with:
✔ active herpes;
✔ bacterial infection;
✔ viral infection;
✔ fungal infection;
✔ pustular lesions of possible infectious origin;
✔ secondary infection.
Treatment may only be reconsidered once the condition has completely resolved.
________________________________________
LOSS OF SKIN INTEGRITY
It should not be performed on:
✔ open wounds;
✔ abrasions;
✔ excoriations;
✔ fissures;
✔ erosions;
✔ recent burns;
✔ sunburn;
✔ incomplete healing;
✔ severe peeling associated with irritation.
The skin surface should be completely intact before a new assessment is carried out.
________________________________________
ACTIVE DERMATOSES IN THE TREATMENT AREA
The presence of active skin inflammation temporarily contraindicates the procedure.
The main conditions include:
✔ eczema;
✔ active dermatitis;
✔ active psoriasis;
✔ inflammatory rosacea;
✔ contact dermatitis;
✔ uncontrolled seborrhoeic dermatitis;
✔ undiagnosed inflammatory flare-ups.
Potential use should only be reconsidered following clinical stabilisation.
________________________________________
ACTIVE ONCOLOGICAL DISEASE
The procedure should not be performed in patients with active oncological disease without specific medical authorisation or assessment.
________________________________________
SITUATIONS REQUIRING THE PROCEDURE TO BE POSTPONED
HIGHLY REACTIVE OR IRRITATED SKIN
The session should be postponed where there is:
✔ spontaneous burning or stinging;
✔ persistent erythema;
✔ severe tightness;
✔ irritative peeling;
✔ generalised intolerance to cosmetics;
✔ disproportionate reactivity;
✔ clear signs of impaired skin barrier function.
In these cases, stabilisation of the skin should be prioritised.
________________________________________
RECENT AESTHETIC PROCEDURES
Application should be postponed following treatments that have sensitised or temporarily altered the skin surface, including:
✔ other chemical peels;
✔ laser or resurfacing;
✔ dermabrasion or microdermabrasion;
✔ microneedling;
✔ surgical procedures;
✔ laser hair removal;
✔ intensive extractions;
✔ any treatment that has caused residual irritation.
The decision should be based on complete recovery of the area and not solely on the time elapsed.
________________________________________
RECENT USE OF IRRITATING ACTIVE INGREDIENTS
Particular consideration should be given to the use of:
✔ topical retinoids;
✔ oral retinoids;
✔ chemical exfoliants;
✔ keratolytics;
✔ benzoyl peroxide;
✔ other products capable of increasing skin sensitivity.
No prescribed treatment should be discontinued without the advice of the responsible healthcare professional.
________________________________________
RECENT HAIR REMOVAL OR SKIN MANIPULATION
The procedure should be postponed following:
✔ waxing;
✔ threading;
✔ depilatory creams;
✔ electrolysis;
✔ aggressive shaving;
✔ mechanical exfoliation;
✔ intense friction of the area.
The skin should have returned to its usual condition before the peel is performed.
________________________________________
RECENT SUN EXPOSURE
Application is not recommended on skin with:
✔ solar erythema;
✔ sunburn;
✔ sensitivity following intense exposure;
✔ peeling induced by ultraviolet radiation;
✔ a recent tan accompanied by irritation.
It should also be postponed when the patient cannot guarantee adequate photoprotection during recovery.
________________________________________
SITUATIONS REQUIRING SPECIFIC ASSESSMENT
A more detailed clinical assessment will be required in patients with:
✔ a history of post-inflammatory hyperpigmentation;
✔ a tendency towards hypertrophic or keloid scarring;
✔ immunosuppression;
✔ uncontrolled diabetes;
✔ impaired wound healing;
✔ relevant systemic diseases;
✔ a history of severe reactions to aesthetic procedures;
✔ medication that may increase photosensitivity or skin fragility;
✔ any medical condition that raises concerns regarding treatment safety.
Where appropriate, medical assessment should be requested before proceeding.
________________________________________
MEDICATION AND PHARMACOLOGICAL TREATMENTS
The patient’s regular medication should be reviewed before the procedure, particularly where it may:
✔ increase photosensitivity;
✔ modify the inflammatory response;
✔ impair healing;
✔ reduce the skin’s recovery capacity;
✔ increase skin fragility;
✔ promote adverse reactions.
Prescribed medication should never be discontinued on the initiative of the patient or the aesthetic professional.
________________________________________
ANTICIPATED NON-COMPLIANCE WITH POST-TREATMENT CARE
The procedure should be reconsidered when the patient is unable to comply with:
✔ daily photoprotection;
✔ temporary discontinuation of irritating products;
✔ the recommended home care;
✔ scheduled reviews;
✔ reporting any unexpected reaction.
Inability to follow these recommendations may increase the risk of complications.
________________________________________
PRE-PROCEDURE CHECKLIST
Before applying Gluconolactone Peel 25%, confirm:
☐ The skin is intact and free from wounds.
☐ There are no active infections.
☐ There is no active herpes.
☐ There are no uncontrolled inflammatory dermatoses.
☐ There is no sunburn or severe irritation.
☐ The patient is not pregnant or breastfeeding.
☐ There is no known history of hypersensitivity to the product.
☐ Recent aesthetic procedures have been reviewed.
☐ Regular medication has been reviewed.
☐ The skin has regained stability following previous treatments.
☐ The patient is able to comply with post-treatment care.
☐ There is a professional indication compatible with the skin’s current condition.
________________________________________
DECISION IN THE EVENT OF A POSSIBLE CONTRAINDICATION
POSTPONE
When the condition is temporary and may resolve following skin recovery.
STABILISE THE SKIN
When there is irritation, severe reactivity or deterioration of skin barrier function.
MODIFY THE STRATEGY
When another procedure is more appropriate for the observed condition.
REQUEST MEDICAL ASSESSMENT
When there are pathologies, medications or medical history requiring further evaluation.
DO NOT PERFORM THE PROCEDURE
When the potential risk exceeds the expected benefit or appropriate safety conditions cannot be guaranteed.
Professional Application
Technical precision and control throughout every stage of the procedure
Gluconolactone Peel 25% is a peel intended exclusively for professional use. It must be applied using a uniform technique, with strict control of the contact time and continuous observation of the skin response.
The characteristic gentleness of Gluconolactone does not eliminate the need to adapt the procedure to the treatment area, the condition of the skin and the tolerance observed during the session.
________________________________________
PRE-TREATMENT PREPARATION
During the days before treatment, the professional may advise the patient to:
✔ avoid intense sun exposure;
✔ maintain adequate photoprotection;
✔ temporarily discontinue retinoids, exfoliants or other irritating cosmetic products where appropriate;
✔ avoid hair removal or procedures that may sensitise the area;
✔ maintain a gentle home skincare routine;
✔ report any recent changes in the condition of the skin.
These recommendations should be individualised according to the patient’s history and the planned protocol.
________________________________________
PREPARATION OF THE TREATMENT AREA
Before applying the peel, the professional should:
✔ completely remove make-up and sunscreen;
✔ cleanse the skin surface;
✔ remove sebum, sweat and cosmetic residues;
✔ dry the area completely;
✔ degrease the skin only when indicated;
✔ visually assess the integrity of the selected treatment area.
Preparation should be carried out without excessive friction or manoeuvres that may unnecessarily increase skin sensitivity.
________________________________________
PROTECTION OF SENSITIVE AREAS
The following areas should be protected or avoided:
✔ eye contour;
✔ lips and mucous membranes;
✔ corners of the mouth;
✔ nasal folds;
✔ skin folds;
✔ recently treated areas;
✔ any area not included in the treatment.
The product must not come into contact with the eyes or mucous membranes.
________________________________________
PEEL APPLICATION
Gluconolactone Peel 25% should be applied in a thin, even layer, following a previously defined sequence.
During application, the following should be monitored:
✔ the amount of product;
✔ the uniformity of distribution;
✔ the absence of product accumulation;
✔ the application sequence;
✔ the elapsed time;
✔ the response of each area;
✔ the sensations reported by the patient.
Additional layers should not be applied automatically. Any adjustment should be justified by the response observed during the procedure.
________________________________________
CONTACT TIME CONTROL
The contact time should be established in accordance with the product’s technical instructions and the characteristics of the treatment area.
The professional should consider:
✔ skin sensitivity;
✔ thickness of the stratum corneum;
✔ anatomical region;
✔ previous experience with chemical peels;
✔ amount applied;
✔ visible response;
✔ reported tolerance.
The maximum contact time represents a limit and not a mandatory target.
________________________________________
OBSERVATION DURING THE SESSION
A mild and transient sensation of tingling, warmth or stinging may occur.
The professional should pay particular attention to:
✔ progressively increasing discomfort;
✔ intense burning;
✔ pain;
✔ excessive erythema;
✔ oedema;
✔ uneven response;
✔ the appearance of whitish areas;
✔ any unexpected reaction.
The clinical response should always take priority over the originally planned contact time.
________________________________________
CRITERIA FOR TERMINATING THE APPLICATION
The procedure should be concluded when:
✔ the established contact time has been reached;
✔ the expected response has been achieved;
✔ significant discomfort occurs;
✔ an excessive reaction is observed;
✔ accidental contact occurs with an area that should not be treated;
✔ the professional considers that continuing may increase the risk.
In the event of an unexpected response, the product should be removed immediately.
________________________________________
PRODUCT REMOVAL
According to the technical information available for this formulation, Gluconolactone Peel 25% does not require conventional chemical neutralisation.
At the end of the contact time, the professional should:
✔ completely remove the product;
✔ pay particular attention to folds and contours;
✔ rinse with water when indicated by the protocol;
✔ dry the surface without friction;
✔ ensure that no residue remains;
✔ assess the skin’s immediate response.
The absence of conventional neutralisation does not alter the need for strict control of the contact time or for complete removal of the product.
________________________________________
IMMEDIATE POST-TREATMENT CARE
After removing the peel, products compatible with the protocol may be applied to:
✔ restore skin comfort;
✔ maintain hydration;
✔ support superficial recovery;
✔ protect the skin against ultraviolet radiation.
Irritating active ingredients, abrasive manoeuvres and vigorous massage of the treated area should be avoided.
________________________________________
HOME CARE INSTRUCTIONS
During the post-treatment period, it is recommended to:
✔ use a gentle cleanser;
✔ maintain adequate hydration;
✔ apply broad-spectrum photoprotection;
✔ avoid direct sun exposure;
✔ temporarily discontinue retinoids, exfoliants and acids;
✔ avoid manually removing any peeling skin;
✔ avoid hair removal and other sensitising procedures;
✔ avoid intense heat for the recommended period;
✔ report any persistent or unexpected reaction.
Whenever possible, these recommendations should be provided in writing.
________________________________________
SESSION RECORD
Professional documentation should include:
✔ treatment area;
✔ initial skin condition;
✔ preparation performed;
✔ amount of product and number of layers;
✔ total contact time;
✔ observed skin response;
✔ sensations reported by the patient;
✔ method of product removal;
✔ products applied afterwards;
✔ home care instructions;
✔ any incidents;
✔ photographic records where consent has been obtained.
________________________________________
ERRORS TO AVOID
✘ applying an excessive amount of product;
✘ allowing product to accumulate in skin folds;
✘ applying the product close to the eyes or mucous membranes;
✘ extending the contact time in an attempt to achieve visible peeling;
✘ applying additional layers without first assessing the response;
✘ performing aggressive skin preparation;
✘ assuming that a PHA cannot cause irritation;
✘ removing the product incompletely;
✘ combining procedures without respecting the recovery period;
✘ automatically repeating the same technique for every patient.
________________________________________
PROFESSIONAL CHECKLIST
☐ The treatment area has been properly cleansed and dried.
☐ Sensitive areas have been protected.
☐ The product has been applied evenly.
☐ The amount of product and the number of layers have been recorded.
☐ The contact time has been monitored.
☐ The response has been observed throughout the entire session.
☐ The product has been completely removed.
☐ The indicated immediate post-treatment care has been applied.
☐ The patient has received home care instructions.
☐ The session has been fully documented.
Clinical Protocols
Strategies adapted to specific therapeutic objectives
Gluconolactone Peel 25% may be incorporated into different professional programmes provided that the indication, treatment area and expected tolerance have been properly assessed.
The protocols presented below constitute general clinical guidance. The amount applied, number of layers, contact time, frequency and duration of the programme should be adjusted at each session according to the observed response.
________________________________________
PROTOCOL FOR STABLE SENSITIVE SKIN
Objective
To promote very superficial exfoliation in skin with reduced tolerance, without initially resorting to more intensive procedures.
May be considered when there is
✔ stable skin sensitivity;
✔ reactivity without active inflammation;
✔ irregular texture;
✔ mild tightness;
✔ low tolerance to other exfoliants;
✔ reduced radiance.
Protocol approach
• Conservative application.
• Adapted contact time.
• Continuous observation of tolerance.
• Complete recovery before a new session.
• Gentle, non-irritating home skincare.
________________________________________
INTENSIVE HYDRATION PROTOCOL
Objective
To improve the superficial condition of dehydrated skin through gradual renewal combined with humectant and restorative care.
May be considered when there is
✔ epidermal dehydration;
✔ sensation of tightness;
✔ loss of superficial flexibility;
✔ rough texture;
✔ fine lines accentuated by dryness;
✔ a dull appearance.
Protocol approach
• Very superficial exfoliation.
• Subsequent application of compatible hydrating products.
• Reinforcement of the home care routine.
• Reassessment of skin comfort and flexibility.
________________________________________
TEXTURE REFINEMENT PROTOCOL
Objective
To progressively smooth the microrelief and improve the uniformity of the skin surface.
May be considered when there is
✔ rough texture;
✔ irregular texture;
✔ superficial accumulation of corneocytes;
✔ loss of smoothness;
✔ visible pores;
✔ dull skin.
Protocol approach
• Localised or full-area treatment according to the region.
• Adaptation of the amount and contact time.
• Assessment of smoothness and regularity between sessions.
• Avoid increasing intensity solely to produce peeling.
________________________________________
PROTOCOL FOR SUPERFICIAL COMEDONES
Objective
To promote gradual exfoliation of the follicular surface in patients with mild imperfections and low tolerance to more intensive keratolytics.
May be considered when there is
✔ open or closed comedones;
✔ blackheads;
✔ visible pores;
✔ mild seborrhoea;
✔ irregular follicular texture.
Protocol approach
• Careful selection of treatment areas.
• Uniform application without aggressive friction.
• Integration with a non-comedogenic home care routine.
• Reassessment of the follicular response.
• Referral or change of strategy where moderate or severe inflammation is present.
________________________________________
RADIANCE AND SUPERFICIAL TONE PROTOCOL
Objective
To progressively improve a dull appearance and promote greater visible uniformity when the irregularities are predominantly epidermal.
May be considered when there is
✔ loss of radiance;
✔ visibly uneven skin tone;
✔ mild superficial marks;
✔ cumulative photo-exposure;
✔ irregular texture.
Protocol approach
• Prior diagnosis of the origin of the alteration.
• Strict daily photoprotection.
• Photographic follow-up where indicated.
• Adaptation of the programme according to pigmentation progression.
________________________________________
PROTOCOL FOR FINE LINES CAUSED BY DEHYDRATION
Objective
To visibly soften superficial lines associated with dryness, reduced flexibility and alteration of the stratum corneum.
May be considered when there is
✔ superficial fine lines;
✔ dehydration;
✔ tightness;
✔ rough texture;
✔ early skin ageing.
Protocol approach
• Very superficial renewal.
• Reinforcement of immediate and home hydration.
• Assessment of skin flexibility.
• Differentiation between dehydration lines and structural wrinkles.
________________________________________
PROTOCOL FOR EARLY PHOTOAGEING
Objective
To address early superficial manifestations associated with cumulative environmental and sun exposure.
May be considered when there is
✔ irregular texture;
✔ reduced radiance;
✔ fine lines;
✔ dehydration;
✔ uneven-looking skin tone.
Protocol approach
• Phased planning.
• Broad-spectrum photoprotection.
• Integration of topical antioxidants where indicated.
• Periodic reassessment of texture and tone.
________________________________________
SKIN PREPARATION PROTOCOL
Objective
To condition the skin surface before introducing another procedure within a sequential treatment plan.
May be considered before
✔ hydrating mesotherapy;
✔ PDRN;
✔ biostimulation;
✔ LED therapy;
✔ Skin Quality programmes;
✔ compatible medical-aesthetic technologies.
Protocol approach
• Improve superficial uniformity beforehand.
• Assess skin tolerance.
• Confirm complete recovery before progressing.
• Do not assume that both procedures should be performed in the same session.
________________________________________
MAINTENANCE PROTOCOL
Objective
To preserve the results achieved through periodic sessions adapted to the evolution of the skin.
May include
✔ occasional applications according to need;
✔ review of the home care routine;
✔ maintenance of hydration;
✔ monitoring of sensitivity;
✔ daily photoprotection;
✔ occasional incorporation of other procedures.
Frequency should be established according to clinical stability and not by means of a fixed schedule.
________________________________________
GENERAL PROGRAMME STRUCTURE
Initial assessment
↓
Definition of the priority objective
↓
Selection of the area and intensity
↓
Application of Gluconolactone Peel 25%
↓
Post-treatment care
↓
Reassessment of tolerance and progression
↓
Maintenance, adaptation or change of strategy
________________________________________
VARIABLES THAT MAY BE MODIFIED
Personalisation of the protocol may involve changes in:
✔ treatment area;
✔ amount of product;
✔ number of layers;
✔ contact time;
✔ frequency;
✔ products used after the peel;
✔ home care routine;
✔ sequence with other procedures.
These variables should be adjusted independently and not all modified simultaneously without clinical justification.
________________________________________
CRITERIA FOR MODIFYING THE PROGRAMME
The protocol should be reassessed where there is:
✔ persistent irritation;
✔ increased sensitivity;
✔ slower recovery than expected;
✔ loss of comfort;
✔ development of infection or dermatosis;
✔ recent sun exposure;
✔ changes in medication;
✔ failure to follow post-treatment care;
✔ lack of progression compatible with the objective;
✔ achievement of the intended results.
Following reassessment, the professional may:
• maintain the strategy;
• reduce the contact time or treatment area;
• space out the sessions;
• temporarily reinforce home care;
• select another procedure;
• discontinue the programme.
________________________________________
PROTOCOL SUMMARY
Main objective Protocol that may be considered
Stable sensitivity Sensitive Skin Protocol
Dehydration Intensive Hydration Protocol
Rough texture Texture Refinement Protocol
Superficial comedones Comedone Protocol
Reduced radiance Radiance Protocol
Irregular superficial tone Visible Uniformity Protocol
Fine lines caused by dryness Fine Lines Protocol
Early photoageing Photoageing Protocol
Preparation for another phase Skin Preparation Protocol
Preservation of results Maintenance Protocol
TherapDerma™ Combinations
Sequential integration of procedures with complementary objectives
Gluconolactone Peel 25% may be incorporated into combined programmes when another procedure provides a different therapeutic function that is not covered by superficial exfoliation.
The combination should be planned sequentially, defining in advance:
✔ the specific objective of each intervention;
✔ the order of the procedures;
✔ the required recovery interval;
✔ the criteria for progressing to the next phase;
✔ the variables that should be reassessed.
The combination of treatments does not necessarily imply that they should be performed during the same session. Compatibility will depend on the selected technique, the condition of the skin and the applicable professional instructions.
________________________________________
GLUCONOLACTONE PEEL 25% + HYDRATING MESOTHERAPY
Superficial renewal and treatment of dehydration
It may be considered when superficial exfoliation needs to be complemented by an intervention aimed at improving skin hydration using a specifically selected professional solution.
Function of each phase
Gluconolactone Peel 25%
✔ promotes regularity of the skin surface;
✔ helps smooth the stratum corneum;
✔ prepares the skin within a therapeutic sequence.
Hydrating mesotherapy
✔ addresses hydration needs not covered exclusively by the peel;
✔ allows active ingredients to be selected according to the diagnosis;
✔ complements programmes aimed at flexibility and comfort.
Mesotherapy should be incorporated when the skin has regained the appropriate conditions for the planned procedure.
________________________________________
GLUCONOLACTONE PEEL 25% + HYALURONIC ACID
Superficial improvement and hydration support
This combination may be considered where dehydration is accompanied by loss of flexibility or superficial fine lines.
Complementary objective
✔ improve the uniformity of the skin surface;
✔ reinforce the hydration strategy;
✔ promote more flexible skin;
✔ visibly reduce lines associated with dryness;
✔ maintain a progressive approach.
The type of hyaluronic acid, its concentration, route of administration and technique used should be defined according to the professional indication.
________________________________________
GLUCONOLACTONE PEEL 25% + PDRN
Epidermal conditioning and subsequent regenerative phase
It may be considered within programmes where there is a clear intention to differentiate an initial phase of superficial improvement from a subsequent phase aimed at regenerative objectives.
Suggested sequence
Very superficial renewal
↓
Complete skin recovery
↓
Professional reassessment
↓
Incorporation of the PDRN protocol
The indication for PDRN should respond to its own clinical objectives and should not be considered an automatic continuation of the peel.
________________________________________
GLUCONOLACTONE PEEL 25% + LED THERAPY
Non-abrasive support within the programme
LED therapy may be incorporated where there is an indication compatible with the treatment objective and the device used.
It may be considered to:
✔ support the post-procedure phase;
✔ complement strategies aimed at comfort;
✔ be incorporated into sensitive skin programmes;
✔ support continuity between sessions;
✔ avoid the immediate introduction of abrasive techniques.
The wavelength, fluence, duration and frequency should be adjusted according to the specific protocol of the device.
________________________________________
GLUCONOLACTONE PEEL 25% + RADIOFREQUENCY
Superficial action and complementary technology
Radiofrequency may form part of a sequential treatment plan when the objective includes aspects that do not depend exclusively on the epidermal surface.
This combination may be considered in programmes aimed at:
✔ fine lines;
✔ loss of firmness;
✔ the visual quality of the skin;
✔ progressive rejuvenation;
✔ comprehensive maintenance.
Radiofrequency should only be applied when the skin has fully recovered and using parameters adapted to the treatment area and the patient.
________________________________________
GLUCONOLACTONE PEEL 25% + BIOSTIMULATION
Different levels of action within the same programme
The peel may be used as an independent phase of superficial improvement before incorporating biostimulation procedures aimed at structural objectives.
Planning objectives
✔ differentiate epidermal renewal from biostimulatory treatment;
✔ avoid unnecessary overlapping of stimuli;
✔ organise the phases of the programme;
✔ establish recovery intervals;
✔ assess the response to each procedure separately.
The biostimulation technique should be selected according to the clinical indication and the applicable professional framework.
________________________________________
GLUCONOLACTONE PEEL 25% + ANTIOXIDANT PROTOCOLS
Complementary strategy against photo-exposure and environmental stress
It may be sequentially combined with topical or professional antioxidant active ingredients when the diagnosis identifies a specific need for protection against oxidative stress.
The combination may be aimed at:
✔ complementing programmes for dull skin;
✔ supporting early photoageing strategies;
✔ helping maintain radiance;
✔ supporting the home care routine;
✔ reinforcing preventive measures.
Antioxidants do not replace daily photoprotection.
________________________________________
GLUCONOLACTONE PEEL 25% + PROTOCOLS FOR IMPERFECTIONS
Gradual exfoliation and complementary home management
In sensitive skin with superficial comedones, visible pores or mild seborrhoea, it may be combined with a professional routine aimed at controlling follicular blockage without causing over-exfoliation.
The programme may include:
✔ non-comedogenic cleansing;
✔ hydration compatible with blemish-prone skin;
✔ selected home care active ingredients;
✔ photoprotection;
✔ periodic reassessment of inflammation;
✔ adaptation of exfoliation frequency.
Moderate or severe inflammatory acne requires a specific approach.
________________________________________
GLUCONOLACTONE PEEL 25% + HOME SKINCARE
Continuity between sessions
The home care routine should complement the procedure without unnecessarily duplicating its exfoliating action.
It may include:
✔ a gentle cleanser;
✔ a humectant moisturiser;
✔ skin barrier support products;
✔ antioxidants where indicated;
✔ specific active ingredients for skin tone or texture;
✔ broad-spectrum photoprotection.
The introduction of new products should be gradual, particularly in patients with a history of cosmetic intolerance.
________________________________________
COMBINATION MATRIX
Complementary need Procedure that may be considered
Persistent dehydration Hydrating mesotherapy
Loss of superficial flexibility Hyaluronic acid
Regenerative objective PDRN
Non-abrasive support LED therapy
Fine lines or loss of firmness Radiofrequency
Structural objectives Biostimulation
Oxidative stress or photo-exposure Antioxidant protocol
Comedones and visible pores Specific programme for imperfections
Continuity between sessions Professional home skincare
________________________________________
CRITERIA FOR PROGRESSING TO THE NEXT PHASE
Before incorporating another procedure, the following should be confirmed:
✔ complete recovery of the treated surface;
✔ absence of persistent irritation;
✔ stability of skin barrier function;
✔ adequate tolerance of the peel;
✔ compatibility between the techniques;
✔ the existence of a distinct indication;
✔ compliance with post-treatment care;
✔ the ability to carry out the required follow-up.
________________________________________
CRITERIA FOR MODIFYING THE COMBINATION
The treatment plan should be reviewed where there is:
✔ slower recovery than expected;
✔ increased sensitivity;
✔ inflammation;
✔ loss of comfort;
✔ an unexpected reaction;
✔ changes in medication;
✔ new intense sun exposure;
✔ modification of the therapeutic objective;
✔ absence of an additional benefit that justifies the next phase.
In these situations, the complementary procedure may be spaced out, replaced or cancelled.
________________________________________
SUGGESTED THERAPEUTIC SEQUENCE
Diagnosis and definition of objectives
↓
Selection of Gluconolactone Peel 25%
↓
Professional application
↓
Skin recovery
↓
Reassessment of the superficial result
↓
Identification of an additional therapeutic need
↓
Selection of the complementary procedure
↓
Specific follow-up of each phase
Combinations should be built around distinct clinical needs and not through the automatic accumulation of procedures.
Frequently Asked Questions (FAQ)
Practical answers for the professional use of Gluconolactone Peel 25%
The following questions address common queries that may arise during the selection, application and follow-up of Gluconolactone Peel 25%.
This section complements the technical information developed in the previous tabs and does not replace individual assessment, the professional protocol or the official product instructions.
________________________________________
WHAT TYPE OF PEEL IS GLUCONOLACTONE PEEL 25%?
It is a professional chemical peel formulated with 25% Gluconolactone, belonging to the Polyhydroxy Acid (PHA) family.
Its primary level of action is the stratum corneum, and it is characterised by very superficial, gradual exfoliation associated with humectant and antioxidant properties.
________________________________________
HOW DOES IT DIFFER FROM AHAs?
Gluconolactone has a comparatively larger molecular size than many Alpha Hydroxy Acids, which promotes slower and predominantly superficial interaction with the skin.
In addition to its exfoliating activity, it contains multiple hydroxyl groups capable of interacting with water molecules, contributing to its humectant profile.
The choice between a PHA and an AHA should be based on the clinical objective, the condition of the skin and the required intensity of action.
________________________________________
CAN IT BE USED ON SENSITIVE SKIN?
It may be considered for sensitive skin when the skin is intact, stable and free from active inflammation.
It should not be applied where there is:
✔ spontaneous burning;
✔ intense erythema;
✔ persistent irritation;
✔ inflammatory peeling;
✔ evident deterioration of skin barrier function;
✔ uncontrolled skin intolerance.
Skin sensitivity does not in itself constitute an automatic indication.
________________________________________
CAN IT BE USED IN PATIENTS WITH ROSACEA?
It should not be applied during active phases involving intense erythema, burning, papules, pustules or high reactivity.
In patients with a history of stable rosacea, its potential use requires specific clinical assessment and a particularly conservative technique.
The presence of rosacea should be interpreted as a situation requiring caution, not as a general indication.
________________________________________
DOES THE SKIN NEED TO PEEL FOR THE TREATMENT TO BE EFFECTIVE?
No.
Peeling may be minimal or barely perceptible due to the gradual action of Gluconolactone.
The response should be assessed through the evolution of:
✔ smoothness;
✔ texture;
✔ hydration;
✔ comfort;
✔ radiance;
✔ superficial uniformity.
More intense peeling does not necessarily imply a better result.
________________________________________
WHAT SENSATIONS ARE COMMON DURING APPLICATION?
A mild and transient sensation of tingling, warmth or stinging may occur.
The product should be removed if the following are observed:
✔ intense burning;
✔ pain;
✔ progressively increasing discomfort;
✔ excessive erythema;
✔ oedema;
✔ an uneven or unexpected response.
The tolerance reported by the patient should be assessed together with visible clinical signs.
________________________________________
DOES IT REQUIRE NEUTRALISATION?
According to the technical information available for this formulation, it does not require conventional chemical neutralisation.
At the end of the contact time, the product should be completely removed in accordance with the professional protocol.
The absence of neutralisation does not allow the exposure time to be freely prolonged or the monitoring of the skin response to be omitted.
________________________________________
HOW LONG SHOULD IT REMAIN ON THE SKIN?
The contact time should be established in accordance with the technical instructions and adapted to:
✔ the treatment area;
✔ the thickness of the stratum corneum;
✔ sensitivity;
✔ previous experience with chemical peels;
✔ the amount applied;
✔ the response observed during the session.
The maximum contact time should be considered a safety limit, not a mandatory target.
________________________________________
HOW MANY LAYERS MAY BE APPLIED?
The number of layers should be defined according to the professional protocol and the skin response.
Layers should not be added automatically or with the aim of producing a more visible reaction.
Each additional layer modifies the total amount of product and the effective contact time and therefore requires specific assessment.
________________________________________
HOW MANY SESSIONS ARE REQUIRED?
There is no universal number.
The duration of the programme will depend on:
✔ the clinical objective;
✔ the initial condition of the skin;
✔ tolerance;
✔ recovery between sessions;
✔ documented progression;
✔ compliance with home care.
Each new application should be justified through professional reassessment.
________________________________________
HOW OFTEN CAN IT BE REPEATED?
Frequency should be adapted to the complete recovery of the skin.
A new session should not be performed while any of the following persist:
✔ irritation;
✔ increased sensitivity;
✔ abnormal peeling;
✔ loss of comfort;
✔ impairment of skin barrier function;
✔ any unresolved reaction.
The absence of visible peeling does not justify automatically shortening the interval.
________________________________________
CAN IT BE USED THROUGHOUT THE YEAR?
It may be considered during different seasons provided that the patient can maintain adequate photoprotection and avoid significant sun exposure during recovery.
The procedure should be postponed in the event of:
✔ sunburn;
✔ erythema following exposure;
✔ peeling induced by ultraviolet radiation;
✔ recent intense exposure;
✔ inability to comply with photoprotection recommendations.
________________________________________
CAN IT BE USED FOR COMEDONES OR VISIBLE PORES?
It may be incorporated as supportive care within gentle protocols aimed at superficial comedones, blackheads, visible pores or mild seborrhoea, particularly in skin with low tolerance to more intensive keratolytics.
It does not replace the specific treatment of moderate or severe inflammatory acne.
________________________________________
CAN IT IMPROVE FINE LINES?
It may visibly soften fine lines associated with dehydration, roughness or reduced flexibility of the stratum corneum.
It is not intended to correct deep wrinkles or structural alterations of the dermis.
________________________________________
CAN IT BE USED FOR SKIN TONE IRREGULARITIES?
It may form part of programmes aimed at predominantly epidermal and correctly diagnosed irregularities.
Before indicating it, the following should be assessed:
✔ the origin of the alteration;
✔ its probable depth;
✔ phototype;
✔ pigmentation risk;
✔ sun exposure;
✔ previous treatments.
Daily photoprotection is essential.
________________________________________
CAN IT BE COMBINED WITH OTHER PROCEDURES?
Yes, when each intervention addresses a different need and the sequence has been correctly planned.
It may be combined sequentially with:
✔ hydrating mesotherapy;
✔ hyaluronic acid;
✔ PDRN;
✔ biostimulation;
✔ LED therapy;
✔ radiofrequency;
✔ antioxidant protocols;
✔ professional home skincare.
Complete recovery should be confirmed before progressing to a potentially sensitising technique.
________________________________________
CAN IT BE USED TO PREPARE THE SKIN FOR OTHER TREATMENTS?
It may be used as an independent superficial conditioning phase when the aim is to improve the regularity, hydration or tolerance of the skin beforehand.
This function does not imply that the following procedure should be performed during the same session.
The sequence will depend on the compatibility of the techniques and the recovery observed.
________________________________________
WHICH PRODUCTS SHOULD BE AVOIDED AFTER THE PEEL?
During the period indicated by the professional, the following should be avoided:
✔ retinoids;
✔ chemical exfoliants;
✔ physical exfoliants;
✔ potentially irritating products;
✔ unauthorised home combinations;
✔ hair removal or sensitising procedures.
Active ingredients should be reintroduced once the skin has completely returned to its usual condition.
________________________________________
WHICH CARE MEASURES ARE THE PRIORITY AFTER THE PROCEDURE?
The patient should maintain:
✔ gentle cleansing;
✔ adapted hydration;
✔ broad-spectrum photoprotection;
✔ avoidance of friction or manipulation;
✔ temporary discontinuation of irritating active ingredients;
✔ monitoring of any unexpected reaction.
Care instructions should be provided in writing whenever possible.
________________________________________
WHICH REACTIONS REQUIRE CONTACTING THE PROFESSIONAL?
The patient should immediately report:
✔ persistent pain;
✔ intense burning;
✔ significant oedema;
✔ vesicles;
✔ crust formation;
✔ progressive erythema;
✔ prolonged irritation;
✔ signs of infection;
✔ any reaction differing from the expected progression explained beforehand.
Early assessment allows appropriate measures to be taken and reduces the risk of complications.
________________________________________
WHAT SHOULD BE RECORDED AT EACH SESSION?
The professional record should include:
✔ treatment area;
✔ preparation performed;
✔ amount and number of layers;
✔ contact time;
✔ observed response;
✔ sensations reported;
✔ method of removal;
✔ post-treatment products;
✔ home care recommendations;
✔ any incidents;
✔ planned modifications for future sessions.
________________________________________
QUICK REFERENCE
Question Answer
Is it an AHA? No. It belongs to the PHA family.
Does it act primarily in depth? No. Its action is predominantly superficial.
Is visible peeling mandatory? No. It may be minimal or imperceptible.
Can it be used on inflamed skin? No. The procedure should be postponed.
Does it require conventional neutralisation? No, according to the available technical information.
Can it be repeated at a fixed frequency? No. The interval depends on recovery.
Can it be combined with other treatments? Yes, in a planned and sequential manner.
Does it replace photoprotection? No.
Is it suitable for all sensitive skin? No. The skin must be stable and intact.
Can it correct deep wrinkles? No. Its action is superficial.
Related Content
Professional resources to support broader clinical planning
Gluconolactone Peel 25% forms part of a professional collection designed to enable the selection of different solutions according to the diagnosis, treatment area and therapeutic objective.
This section brings together the main TherapDerma resources related to the product and facilitates access to complementary information on peels, mesotherapy, technologies, professional skincare and clinical support tools.
________________________________________
THERAPDERMA PEELING COLLECTION™
Different active ingredients for different clinical objectives
The TherapDerma professional peel collection includes formulations with different mechanisms and levels of action:
✔ Glycolic Peel;
✔ Lactic Peel;
✔ Gluconolactone Peel;
✔ Malic Peel;
✔ Mandelic Peel;
✔ Salicylic Peel;
✔ Pyruvic Peel;
✔ TCA Peel.
Selection should not be based solely on concentration. Each formulation should be assessed according to the skin profile, the required depth of action and the purpose of the procedure.
________________________________________
THERAPDERMA MESOTHERAPY COLLECTION™
Solutions for complementary therapeutic phases
The TherapDerma mesotherapy collection brings together professional formulations intended for different treatment areas:
✔ hydration;
✔ revitalisation;
✔ Skin Quality;
✔ regeneration;
✔ biostimulation;
✔ body treatments;
✔ hair protocols.
These solutions may be incorporated sequentially when there is a clinical need different from the one addressed by the peel.
________________________________________
THERAPDERMA TECHNOLOGIES™
Equipment to broaden therapeutic possibilities
The TherapDerma technology range enables certain professional programmes to be complemented through procedures adapted to different objectives.
The choice of equipment, parameters and timing of integration should be based on:
✔ the clinical indication;
✔ the treatment area;
✔ compatibility with previous procedures;
✔ the current condition of the skin;
✔ the specific purpose of the technology.
________________________________________
THERAPDERMA CLINICAL PROTOCOLS™
Tools for structuring treatment
TherapDerma clinical protocols provide guidance intended to organise the different phases of a professional procedure.
They may include information on:
✔ patient selection;
✔ skin preparation;
✔ application sequence;
✔ post-treatment care;
✔ follow-up criteria;
✔ treatment adaptation;
✔ integration with other solutions.
Protocols are support tools and should be applied in accordance with professional judgement and the technical instructions for each product.
________________________________________
THERAPDERMA SKINCARE™
Home care continuity between sessions
The TherapDerma professional skincare range may be used to support the skin before and after procedures carried out in the clinic.
Categories related to peel programmes include:
✔ gentle cleansing;
✔ hydration;
✔ support for skin barrier function;
✔ antioxidant protection;
✔ management of skin tone irregularities;
✔ photoprotection;
✔ maintenance of skin quality.
The routine should be selected according to the skin type, the procedure performed and the observed progression.
________________________________________
RECOMMENDED PROFESSIONAL RESOURCES
For further information, the following may be consulted:
✔ Complete TherapDerma™ Peel Catalogue;
✔ TherapDerma Mesotherapy Collection™;
✔ TherapDerma Clinical Protocol Manual™;
✔ TherapDerma Clinical Decision Guide™;
✔ TherapDerma™ Combination Guide;
✔ TherapDerma™ Professional Skincare Guide;
✔ official technical data sheets for each formulation;
✔ TherapDerma Professional Academy™ training materials.
________________________________________
REFERENCE GUIDE ACCORDING TO NEED
Professional need Recommended resource
Compare different peels Complete Peel Catalogue
Select a protocol Clinical Protocol Manual
Integrate other procedures Combination Guide
Choose a mesotherapy solution Mesotherapy Collection
Plan home care Professional Skincare Guide
Support decision-making Clinical Decision Guide
Develop clinical knowledge Professional Academy
Confirm technical parameters Official technical data sheet
________________________________________
ACCESS TO THE PROFESSIONAL ECOSYSTEM
Chemical peels
↓
Mesotherapy
↓
Medical-aesthetic technologies
↓
Professional skincare
↓
Clinical protocols
↓
Decision-making tools
↓
Specialist training
Each resource fulfils a specific function and enables broader planning possibilities without turning every treatment into the same therapeutic sequence.
TherapDerma Professional Academy™
Where knowledge becomes clinical judgement
The continuous evolution of aesthetic medicine requires ongoing professional development capable of integrating science, technique and clinical reasoning.
TherapDerma Professional Academy™ is an international educational platform designed for physicians, nurses, pharmacists, dentists and other professionals authorised to practise within the legal and professional framework applicable in each country.
Its purpose is not merely to explain products or reproduce techniques. It aims to develop the professional’s ability to interpret scientific information, analyse clinical situations and support every therapeutic decision with sound clinical reasoning.
________________________________________
OUR MISSION
Developing knowledge applicable to professional practice
TherapDerma Professional Academy™ programmes are designed to help professionals:
✔ understand the biological foundations of treatments;
✔ interpret the properties of each formulation;
✔ relate diagnosis to therapeutic selection;
✔ recognise indications, limitations and risk situations;
✔ design strategies adapted to specific objectives;
✔ critically evaluate clinical outcomes;
✔ maintain continuous professional development.
Education gains value when it positively enhances analytical ability and everyday clinical practice.
________________________________________
THERAPDERMA EDUCATIONAL MODEL™
From information to professional decision-making
Acquire knowledge
↓
Understand the scientific foundation
↓
Analyse the clinical situation
↓
Compare alternatives
↓
Select the strategy
↓
Apply with clinical judgement
↓
Evaluate outcomes
↓
Update knowledge
This model promotes continuous learning and prevents education from being limited to memorising fixed protocols.
________________________________________
AREAS OF TRAINING
Programmes may cover:
✔ chemical peels;
✔ skin physiology and barrier function;
✔ Skin Quality;
✔ mesotherapy;
✔ PDRN;
✔ biostimulation;
✔ medical-aesthetic technologies;
✔ professional skincare;
✔ safety and complication prevention;
✔ clinical documentation;
✔ standardised photography;
✔ case analysis;
✔ patient communication;
✔ scientific updates.
Each area is developed using an approach adapted to the participants’ level of experience and professional profile.
________________________________________
TRAINING FORMATS
TherapDerma Professional Academy™ may provide education through:
✔ face-to-face courses;
✔ online training;
✔ scientific webinars;
✔ practical workshops;
✔ specialised masterclasses;
✔ clinical case analysis;
✔ update sessions;
✔ professional congresses and meetings;
✔ technical reference materials.
The format selected will depend on the content, learning objectives and practical component required.
________________________________________
TRAINING IN CHEMICAL PEELS
Beyond application technique
Specialised training in chemical peels may include:
✔ classification of hydroxy acids;
✔ differences between AHAs, BHAs, PHAs and other agents;
✔ physicochemical properties of formulations;
✔ the relationship between concentration, pH and clinical behaviour;
✔ assessment of the skin surface;
✔ patient selection;
✔ adaptation of the technique;
✔ recognition of expected and unexpected responses;
✔ post-treatment care;
✔ sequential integration with other procedures.
The objective is to understand why a formulation may be appropriate for one patient but not for another.
________________________________________
CASE-BASED TRAINING
Clinical cases enable theoretical knowledge to be applied to real or simulated situations.
Case analysis may include:
✔ reason for consultation;
✔ relevant medical history;
✔ skin condition;
✔ differential diagnosis;
✔ possible objectives;
✔ therapeutic alternatives;
✔ decision taken;
✔ observed outcome;
✔ need to modify the treatment;
✔ lessons learned from the case.
This approach encourages professional reasoning and allows different decisions to be analysed without reducing practice to a single predetermined answer.
________________________________________
WHAT MAKES THERAPDERMA PROFESSIONAL ACADEMY™ DIFFERENT?
It does not simply show how to apply a product.
It teaches how to interpret its formulation.
It does not simply present a protocol.
It teaches how to justify every procedural variable.
It does not simply describe indications.
It teaches how to differentiate between apparently similar patients.
It does not simply teach combinations.
It teaches how to define the specific role of each intervention.
It does not simply present results.
It teaches how to evaluate the quality of evidence and clinical outcomes.
________________________________________
PROFESSIONAL COMPETENCIES
Training may contribute to the development of competencies related to:
✔ clinical analysis;
✔ scientific interpretation;
✔ therapeutic selection;
✔ risk prevention;
✔ technical adaptation;
✔ documentation;
✔ professional communication;
✔ follow-up;
✔ critical thinking;
✔ independent learning.
These competencies complement practical experience and help maintain a more consistent professional practice.
________________________________________
CONTINUOUS PROFESSIONAL DEVELOPMENT
TherapDerma Professional Academy™ develops new educational content to support the evolution of the sector through:
✔ scientific reviews;
✔ protocol updates;
✔ new technical materials;
✔ themed seminars;
✔ integration of emerging technologies;
✔ analysis of clinical trends;
✔ case reviews;
✔ advanced specialisation programmes.
Professional development should be understood as a continuous process rather than an isolated educational activity.
________________________________________
ACADEMY PRINCIPLES
✔ Science before trends.
✔ Understanding before application.
✔ Diagnosis before selection.
✔ Safety before intensity.
✔ Personalisation before standardisation.
✔ Reassessment before repetition.
✔ Continuous education before static knowledge.
________________________________________
THERAPDERMA CONCLUSION
TherapDerma Professional Academy™ has been created to transform scientific information and clinical experience into practical tools for professional practice.
Its mission is not simply to provide product training, but to develop professionals capable of analysing, deciding, applying and reassessing every treatment with greater scientific and clinical foundation.
Because a technique can be learned.
Clinical judgement must be built, continuously updated and constantly refined.
TherapDerma Clinical Decision System™
Turning clinical information into individualised therapeutic decisions
The TherapDerma Clinical Decision System™ (TCDS™) is a structured framework for professional reasoning designed to help determine whether Gluconolactone Peel 25% is the appropriate option for a specific patient.
Its purpose is not to reproduce a technical protocol, but to organise the decisions that precede and follow the procedure:
✔ assess the current condition of the skin;
✔ identify the primary clinical need;
✔ determine whether the required intervention is superficial;
✔ evaluate the suitability of the peel;
✔ establish the appropriate level of intervention;
✔ interpret the response obtained;
✔ decide on programme continuity;
✔ document the rationale behind every decision.
The system does not replace professional judgement, legally recognised competencies or the product’s official technical instructions.
________________________________________
STEP 1
DEFINE THE CLINICAL PROBLEM
Before selecting the peel, the professional should identify the condition that is genuinely motivating the treatment.
The assessment should answer the following questions:
✔ What is the patient’s main reason for consultation?
✔ Which characteristic of the skin is intended to be improved?
✔ Is the condition predominantly superficial?
✔ Is there a single primary need or several simultaneous needs?
✔ What outcome can reasonably be expected from a PHA?
Selection should not be based solely on general descriptions such as “sensitive skin”, “dull skin” or “dehydrated skin”.
________________________________________
STEP 2
DETERMINE SKIN STABILITY
Sensitive skin is not always ready to undergo a peel.
Before proceeding, it is important to distinguish between:
STABLE SENSITIVE SKIN
✔ intact skin surface;
✔ absence of active inflammation;
✔ controlled reactivity;
✔ tolerance compatible with a superficial intervention;
✔ adequate recovery capacity.
COMPROMISED SKIN
✔ persistent erythema;
✔ spontaneous burning sensation;
✔ irritant desquamation;
✔ inflammation;
✔ obvious impairment of barrier function;
✔ recent reaction to cosmetics or procedures.
When the skin is compromised, the priority should be stabilisation rather than exfoliation.
________________________________________
STEP 3
CONFIRM GOAL COMPATIBILITY
Gluconolactone Peel 25% may be considered when the primary objective is to address:
✔ superficial dehydration;
✔ rough or uneven texture;
✔ reduced radiance;
✔ fine lines associated with dryness;
✔ mild epidermal tone irregularities;
✔ superficial comedones in low-tolerance skin;
✔ the need for very gradual exfoliation;
✔ maintenance of superficial skin quality.
An alternative strategy should be selected when the objective requires specific management of:
✔ moderate or severe inflammatory acne;
✔ deep pigmentation;
✔ scars;
✔ structural wrinkles;
✔ significant skin laxity;
✔ active dermatological conditions.
________________________________________
STEP 4
CONFIRM THE SUITABILITY OF THE PEEL
The indication may be considered appropriate when the following conditions are met:
1. There is a clearly defined superficial need
The condition is primarily located within the stratum corneum or affects the appearance of the skin surface.
2. A gradual intervention is required
The anticipated tolerance suggests that a more intensive exfoliation should initially be avoided.
3. The skin is stable
There are no clinical signs requiring the procedure to be postponed.
4. The patient understands the scope of the treatment
Expectations are compatible with gradual improvement and the possibility of minimal desquamation.
If any of these conditions are not met, the selection should be reconsidered.
________________________________________
STEP 5
DEFINE THE INTERVENTION STRATEGY
Once the indication has been confirmed, the overall treatment strategy should be established.
The professional will decide:
✔ whether the treatment will be full-face or localised;
✔ which areas should be excluded;
✔ the level of caution required for the skin;
✔ which variable will be used to control intensity;
✔ which signs will justify early termination;
✔ which outcome should be assessed after recovery.
Personalisation does not consist of modifying multiple variables simultaneously, but of making controlled adjustments that can subsequently be interpreted.
________________________________________
STEP 6
ESTABLISH SUCCESS CRITERIA
Before beginning the procedure, specific parameters should be defined to evaluate the outcome.
Depending on the objective, the following may be assessed:
✔ reduction in the sensation of tightness;
✔ improvement in smoothness;
✔ greater uniformity of the skin microrelief;
✔ restoration of radiance;
✔ visible reduction of dehydration-related fine lines;
✔ improvement in the appearance of pores or comedones;
✔ stability of skin tolerance;
✔ absence of unexpected reactions.
The intensity of desquamation should not be used as the primary criterion for success.
________________________________________
STEP 7
INTERPRET THE RESPONSE
Following the session, the response should be classified objectively.
FAVOURABLE RESPONSE
✔ good tolerance;
✔ recovery within the expected timeframe;
✔ improvement consistent with the objective;
✔ absence of persistent irritation;
✔ skin stability.
PARTIAL RESPONSE
✔ good tolerance;
✔ subtle improvement;
✔ limited but consistent benefit;
✔ need to continue or adapt the programme.
INADEQUATE RESPONSE
✔ prolonged irritation;
✔ loss of comfort;
✔ increased reactivity;
✔ incomplete recovery;
✔ lack of correspondence between the indication and the outcome;
✔ occurrence of an unexpected reaction.
This classification facilitates subsequent decision-making and avoids automatically repeating the same strategy.
________________________________________
STEP 8
DECIDE ON CONTINUATION
Following reassessment, different decisions may be taken:
MAINTAIN
When the response is favourable and the objective remains valid.
ADAPT
When tolerance is good but a specific variable requires modification.
EXTEND THE INTERVAL
When recovery is slower or the skin requires additional time.
REFORMULATE THE OBJECTIVE
When progression shows that the initial need has changed.
ADD ANOTHER PHASE
When the superficial objective has been achieved and there is a separate indication for another procedure.
DISCONTINUE
When intolerance occurs, the indication is no longer present, or the balance between benefit and risk becomes unfavourable.
________________________________________
STEP 9
DOCUMENT THE DECISION
The clinical record should not be limited to describing what was applied.
It should also explain why each decision was made.
It may include:
✔ identified clinical problem;
✔ primary objective;
✔ reasons for selecting Gluconolactone Peel 25%;
✔ criteria for skin stability;
✔ strategy used;
✔ observed parameters;
✔ classified response;
✔ subsequent decision;
✔ justified modifications;
✔ date and purpose of the next review.
Documentation helps build a coherent clinical sequence and enables comparison of progress between sessions.
________________________________________
TCDS™ ALGORITHM
Identify the clinical problem
↓
Is the condition predominantly superficial?
NO
Select another strategy
YES
↓
Is the skin intact and stable?
NO
Postpone and stabilise
YES
↓
Is a gradual, high-tolerance intervention required?
NO
Consider another professional solution
YES
↓
Select Gluconolactone Peel 25%
↓
Define the strategy and success criteria
↓
Perform the procedure according to the technical protocol
↓
Classify the response
↓
Maintain · Adapt · Extend the Interval · Combine · Discontinue
↓
Document the decision
________________________________________
RAPID DECISION MATRIX
Observed situation Decision that may be considered
Sensitive, intact and stable skin Consider the peel
Sensitive skin with active inflammation Postpone
Superficial dehydration Consider within a hydration programme
Rough texture with good anticipated tolerance Consider the procedure
Predominantly superficial fine lines Consider with realistic expectations
Mild comedones in stable reactive skin Consider a gradual strategy
Inflammatory acne Select a specific management approach
Diagnosed epidermal pigmentation disorder Consider with follow-up
Deep or uncertain pigmentation Perform a separate assessment
Good tolerance with progressive benefit Maintain or adapt
Incomplete recovery Extend the interval or postpone
Persistent irritation Discontinue and reassess
Superficial objective achieved Consider maintenance or another therapeutic phase
________________________________________
KEY QUESTIONS BEFORE MAKING A DECISION
✔ What specific condition is being treated?
✔ Can it be managed through a very superficial intervention?
✔ Is the skin currently stable?
✔ Why choose a PHA rather than another alternative?
✔ What outcome should be observed for the session to be considered beneficial?
✔ Which sign would require the procedure to be modified or discontinued?
✔ What information should be obtained before repeating the procedure?
✔ Is there a clinical reason to introduce another phase?
✔ What decision will be documented after reassessment?
________________________________________
BENEFITS OF THE THERAPDERMA CLINICAL DECISION SYSTEM™
The TCDS™ may help to:
✔ avoid selections based solely on skin type;
✔ distinguish indication from potential tolerance;
✔ relate every procedure to a specific objective;
✔ define success criteria before treatment;
✔ interpret subtle responses without relying on desquamation;
✔ reduce automatic repetition;
✔ justify programme modifications;
✔ distinguish maintenance from intensification;
✔ improve traceability of decisions;
✔ structure a more coherent clinical practice.
________________________________________
THE CORE PRINCIPLE OF THE TCDS™
Assess before selecting.
↓
Define before applying.
↓
Observe before modifying.
↓
Reassess before repeating.
↓
Document before continuing.
________________________________________
THERAPDERMA CONCLUSION
The TherapDerma Clinical Decision System™ transforms the use of Gluconolactone Peel 25% into a reasoned process that begins with identifying a specific clinical need and ends with a documented clinical decision.
Its principal value lies in avoiding two common mistakes: assuming that all sensitive skin is suitable for the procedure, and assuming that a high-tolerance formulation can be applied without a defined strategy.
Selection is appropriate when there is a compatible superficial condition, the skin is stable, and the objective can be achieved through a gradual intervention.
From that point onwards, every subsequent decision should be based on the response obtained rather than on the automatic repetition of the protocol.
+1 (786) 546-8347 (Office)
